Jump to content

SLA - SILK LASER AUSTRALIA LIMITED


ShareCafe

Recommended Posts

  • Replies 43.2k
  • Created
  • Last Reply

Top Posters In This Topic

  • chiller

    2097

  • diana

    1910

  • Livas1

    4166

  • jezzabot

    2629

Top Posters In This Topic

Posted Images

If my liver was failing ,and it was life or death, i certainly wouldn't be waiting around to see if for a more refuitable country can come up with a solution, and i dont think car dealers are a very good example just because they hide under a fancy banner,watch T.V. last night?so much for refutable brands
Link to comment
Share on other sites

Exactly the point I am making...

 

It is about credibnility of the organisation.

 

Mesoblast has gone about it in that way - you look at the board and you trust it ...

 

The problem with China stem cells is ... say no more.....

 

Thats the point I am making about how you must present yourself if you want to be taken with credibility.

 

If SLA does it in Russia, you need to look at your market. They say:

 

Our strategy is to use this research as a basis for a focussed trials program aimed at registering BioeffectivesÃÆâ€â„¢ÃƒÆ’ƒÂ¢Ãƒ¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚® as pharmaceuticals, or positioning them as complementary medicines, biologically active nutritional additives, or as new dietary ingredients, under the regulatory regimes in place in different countries.

 

In that case they will not succeed as a pharmaceutical in a country that has a health system based on evidence based medicine and science.

 

They will succeed in gettting them through as "complementary medicines, biologically active nutritional additives, or as new dietary ingredients" but that is a different market and a different profit for the company.

Vagif is also part of the problem. He doesnt have scientific credibility.

 

No one called Soultanov has ever had a publication that I can find in the US National Library of Medicine (Medline). A measure of the scientific credibility of the journal and therefore the article (but yes plenty of articles on altenrative medicine therapies if the trials are worthwhile).

 

So what has Vagif published...

 

http://ieeexplore.ieee.org/xpl/freeabs_all...;isnumber=14635

 

You can see why he is working in the area of alternative medicine and naturopathy - not scientific medicine.

 

The take home message - in your future sales projections for this company - be very very careful about assuming that a hospital, health fund, HMO or any similar organisation will be paying significant amounts for what is a "complementary medicines, biologically active nutritional additives, or as new dietary ingredients"

Link to comment
Share on other sites

If my liver was failing ,and it was life or death, i certainly wouldn't be waiting around to see if for a more refuitable country can come up with a solution,

 

No problems... but a couple of points

 

you would be taking a "complementary medicines, biologically active nutritional additives, or as new dietary ingredients,"

 

it would be an individual decision to deny oneself proven science as a therapy in favour of unproven therapy, but you wouldnt be the first person. As long as patients make an informed decision, then it is their choice.

Link to comment
Share on other sites

Skorpian

It is my understanding that St Vincent's Hospital in Melbourne is currently undertaking a controlled experiment into the efficacy of bioffectives for helping alleviate the effects of alcoholism. On the assumption that the results prove positive (?!) how does this kind of pure research sit with your previous comments? Surely the "scientific" community will sit up and take notice ...?

Link to comment
Share on other sites

chum1155

 

It is a good start - an independent trial (independent of SLA) ... it is an expensive road to go down... but you have to if youa re going to gain that credibility.

 

One of the difficulties with these trials is the endpoints are not always easy to measure and therefore the trials need to be more powerful which eventually means big trials and expensive trials.

 

This is what the company needs to do - to gain entry to the medical arena - but one needs to be realistic about the expected price paid for the drug in the end. First to show efficacy in a controlled trial, then to show efficacy is greater than current therapies, then to show cost effectiveness. It is a long road .... (and dont all those who invest in CST know it !)

 

I recall one of my earlier investments Clinical Cell Culture failed for the reason that the inventors knew it was good, believed it was good but never did the studies.... and they are still getting them done years later...

Link to comment
Share on other sites

My posts still stands correct in there content skorpian.

 

To make this simply plain for you, I have NEVER factored in sales of Ropen as a pharma product (nor has the coy) in any country other than Russia. I do understand biotechs and the trialling system stages 1,2 and 3 as first noted, and I would not touch any biotech following this path as it will take around a decade if successful, and huge costs. I do not invest that far out, I invested in SLA for its more immediate cash flow.

 

Our strategy is to use this research as a basis for a focussed trials program aimed at registering BioeffectivesÃÆâ€â„¢ÃƒÆ’ƒÂ¢Ãƒ¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚® as pharmaceuticals, or positioning them as complementary medicines, biologically active nutritional additives, or as new dietary ingredients, under the regulatory regimes in place in different countries.

 

Their business plan that i referred to is to sell ropen in Russia this year for the 4 figure quoted which has been accepted by the Russian authorites. They will also with their Asian associates be selling bioeffectives as complementary medicines, biologically active nutritional additives, additives to cosmetics, utilized in animal husbandry ( an alternative to antibiotics), equine remendies, or as new dietary ingredients, which have approval for such.

 

FURTHER down the track, with healthy cash flows, they will be able to start proper clinical trials to achieve stage 1, 2 and 3 acceptance. So your comments about this stage if you were familiar with their business plan are not relevant whatsoever in the next few years.

Link to comment
Share on other sites

If the directors of Solagran can get established in a market which does not require the financially crippling clinical trials process, then all power to them. The Russian market should be ample for the next couple of years what with the massive alchoholism going on in that country. Once revenues are rolling in, then they can worry about the FDA process if they want to have Ropren registered in the west. The commercialisation path open to Solagran is not one open to many other fledgling biotecs, because Russia is seldom the initial target market.

 

 

Link to comment
Share on other sites

So your comments about this stage if you were familiar with their business plan are not relevant whatsoever in the next few years.

 

Rileyi

 

I had understood the use of pharmaceuticals in this statement by the company to mean what I was talking about and what I notice a lot of the posters on this thread are talking about when they start talking about issues outside of Russia.

 

Our strategy is to use this research as a basis for a focussed trials program aimed at registering BioeffectivesÃÆâ€â„¢ÃƒÆ’ƒÂ¢Ãƒ¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚® as pharmaceuticals, or positioning them as complementary medicines, biologically active nutritional additives, or as new dietary ingredients, under the regulatory regimes in place in different countries.

I agree from what you have posted you have not factored it in. Personally I would never trust the Russian health system but we will not go there.

 

Good luck with your investment and glad you have thought carefully about it.

 

 

Link to comment
Share on other sites

G'day Chiller.

I had never come across him before here, so did not know his background. He obviously was not uptodate with the coys business plan, as I have never seen any references to Ropen forecasts other than in Russia, nor have I seen any postings by members here on such. If there has been, I may have missed it realising it was irrelevant. Correction, there has been mentioned some sales at about $3k each in NZ and elsewhere, but these are so minimal they are not worth considering. It is available in Oz for example , but only via recommendation from a doctor, and as far as I know, there is only such doc in Melb.

Just a bit of smokescreen from someone not fully understanding the coy.

By the way, I like the chearier avatar, much better than those snappy little dogs with attitude. It has done wonders for your persona, lol.

Have a great day, and lets hope this license isnt too far off.

Link to comment
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now

×
×
  • Create New...